SEC Filing | Vaccinex, Inc.

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

FRIEDBERG ALBERT

(Last)

(First)

(Middle)

181 BAY STREET, SUITE 250

(Street)

TORONTO

M5J 2T3

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/09/2018

3. Issuer Name and Ticker or Trading Symbol
VACCINEX, INC. [ VCNX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	444,294	I	By FCMI Parent Co.⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series D Convertible Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	439,555	⁽²⁾	D
Series A Convertible Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	37,633	⁽²⁾	I	By Pan-Atlantic Bank & Trust Ltd.⁽³⁾
Option (right to acquire)⁽⁴⁾	⁽⁴⁾	⁽⁴⁾	Common Stock	967,983	⁽⁴⁾	I	By FCMI Financial Corporation⁽⁵⁾
Series A Convertible Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	500,570	⁽²⁾	I	By FCMI Parent Co.⁽¹⁾
Series B Convertible Preferred Stock	⁽⁶⁾	⁽⁶⁾	Common Stock	599,957	⁽⁶⁾	I	By FCMI Parent Co.⁽¹⁾
Series B1 Convertible Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	204,145	⁽²⁾	I	By FCMI Parent Co.⁽¹⁾
Series B2 Convertible Preferred Stock	⁽⁷⁾	⁽⁷⁾	Common Stock	480,822	⁽⁷⁾	I	By FCMI Parent Co.⁽¹⁾
Series D Convertible Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	683,681	⁽²⁾	I	By FCMI Parent Co.⁽¹⁾

1. Name and Address of Reporting Person^*

FRIEDBERG ALBERT

(Last)

(First)

(Middle)

181 BAY STREET, SUITE 250

(Street)

TORONTO

M5J 2T3

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

FCMI Parent Co.

(Last)

(First)

(Middle)

181 BAY STREET

SUITE 250

(Street)

TORONTO

M5J 2T3

(City)

(State)

(Zip)

Explanation of Responses:

1. Albert D. Friedberg is the majority owner, a director and the president of FCMI Parent Co. Mr. Friedberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

2. The reported securities will convert into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering.

3. Mr. Friedberg is the majority owner of Pan Atlantic Bank & Trust Ltd. Mr. Friedberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

4. Limited partnership units of Vaccinex Products, LP, which are exchangeable into shares of Common Stock on a 1-for-10 basis at the holder's option.

5. FCMI Financial Corp. is a wholly owned subsidiary of FCMI Parent Co. Mr. Friedberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

6. The reported securities will convert into shares of Common Stock on a 0.1641-for-1 basis immediately prior to the consummation of the Issuer's initial public offering.

7. The reported securities will convert into shares of Common Stock on a 0.124-for-1 basis immediately prior to the consummation of the Issuer's initial public offering.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Scott E. Royer, Attorney-in-Fact	08/09/2018
	FCMI PARENT CO. BY: /s/ Dan Scheiner, Vice President	08/09/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

VACCINEX, INC.

SECTION 16

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Maurice Zauderer, Scott E. Royer and Raymond E. Watkins, each for so long as he is an officer of Vaccinex, Inc. (the "Company"), the undersigned's true and lawful attorney-in-fact to:

(1)

execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

(2)

do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3)

take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 26^th day of July, 2018.

/s/ Albert D. Friedberg_______________

Albert D. Friedberg